Lidocaine 5% Transdermal Patch Shortage
Last Updated: May 7, 2024
Status: Current
Products Affected - Description
-
- Lidoderm transdermal patch, Endo Pharmaceuticals, 5%, 30 count, NDC 63481-0687-06 - discontinued
- Lidocaine transdermal patch, Par Pharmaceuticals, 5%, 30 count, NDC 00603-1880-16
- Lidocaine transdermal patch, Teva, 5%, 30 count, NDC 00591-3525-30
Reason for the Shortage
-
- Amneal has lidocaine 5% transdermal patches available.
- Endo discontinued Lidoderm patches in January 2023.
- Mylan has lidocaine 5% transdermal patches available.
- Par did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.
- Yaral Pharma has lidocaine 5% transdermal patches available.
Available Products
-
- Lidocaine transdermal patch, Amneal, 5%, 30 count, NDC 65162-0791-08
- Lidocaine transdermal patch, Mylan (Viatris), 5%, 30 count, NDC 00378-9055-93
- Lidocaine transdermal patch, Yaral Pharma, 5%, 30 count, NDC 82347-0505-05
Estimated Resupply Dates
-
- Par has lidocaine 5% transdermal patches in 30 count boxes in limited supply.
- Teva has lidocaine 5% transdermal patches in 30 count boxes on back order and the company estimates a release date in early-June 2024.
Updated
Updated May 7, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 9, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.